4.7 Review

Small molecule SIRT1 activators for the treatment of aging and age-related diseases

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 35, Issue 3, Pages 146-154

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2013.12.004

Keywords

sirtuin; deacetylase; STAC; allosteric activator; aging; chromatin; diabetes; cancer; cardiovascular disease; inflammation

Funding

  1. NIA NIH HHS [R37 AG028730, R01 AG028730, R01 AG019719] Funding Source: Medline

Ask authors/readers for more resources

Recent studies in mice have identified single molecules that can delay multiple diseases of aging and extend lifespan. In theory, such molecules could prevent dozens of diseases simultaneously, potentially extending healthy years of life. In this review, we discuss recent advances, controversies, opportunities, and challenges surrounding the development of SIRT1 activators, molecules with the potential to delay aging and age-related diseases. Sirtuins comprise a family of NAID(+)-dependent deacylases that are central to the body's response to diet and exercise. New studies indicate that both natural and synthetic sirtuin activating compounds (STACs) work via a common allosteric mechanism to stimulate sirtuin activity, thereby conferring broad health benefits in rodents, primates, and possibly humans. The fact that two-thirds of people in the USA who consume multiple dietary supplements consume resveratrol, a SIRT1 activator, underscores the importance of understanding the biochemical mechanism, physiological effects, and safety of STACs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available